tbuckley/cabot-search huggingface dataset:
CRITERIA FOR PROPHYLAXIS IN ACTIVE TUBERCULOSIS
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM EUROPE.Major Girard, Surgeon U. S. Army, to Professor Senn.
Authors: A. C. Girard
Journal: JAMA (1894)

No. I. SEA VOYAGE—BREMEN—GÖTTINGEN— DR. HILDEBRANDT—PROFESSOR KOENIG AND THE GÖTTINGEN CLINIC— PROFESSOR ORTH. GÖTTINGEN, Feb. 9, 1894. <h3>Dear Dr. Senn:</h3> —In compliance with your request and the invitation of Dr. Hamilton, I will commence a series of letters, relating what, in my travels, I may find of interest to the profession. Owing to my appointment as delegate from the War Department to the International Congress at Rome, my professional tour in Germany has to be somewhat curtailed, but I hope to supplement this loss by an account of my experiences in the " Eternal City." As a preface I desire to say that I do not expect or hope to compete with your inimitable style in the "Four Months Among the Surgeons of Europe." My account will also not be in chronological form, hence the dates of my visits and their durations will be omitted. The passage in the steamer gave
Immunocytochemistry in Tumor Diagnosis Workshop
Journal: JNCI Journal of the National Cancer Institute (1984)

Immunocytochemistry in Tumor Diagnosis Workshop Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 5, May 1984, Page 1209, https://doi.org/10.1093/jnci/72.5.1209-d Published: 01 May 1984
Diazoxide
Authors: William A. Tansey
Journal: JAMA (1973)

<h3>To The Editor.—</h3> The "Evaluation of Diazoxide (Hyperstat I.V.)" (224:1422, 1973) indicates that severe hypotension is rare when this agent is used. In our series of 140 injections of 300 mg of diazoxide given to 33 patients, four episodes of hypotension occurred. In each instance there was a fall in supine systolic blood pressure to less than 90 mm Hg and a decrease in mean blood pressure greater than 55%. One patient, with a subarachnoid hemorrhage, received an injection of 7.3 mg/kg, considerably higher than the usual dose (4.74 ±.83 mg/kg) in our experience. Two patients had been given concurrent doses of potential vasodilators—one receiving aminophylline and the other, hydralazine hydrochloride. A fourth patient with a history of chronic hypertension refractory to routine antihypertensive therapy received an oral dose of methyldopa, a parenteral dose of phenobarbital, and an infiltrate dose of diazoxide within one hour prior to an effective diazoxide
OC-037 6 year disease durability outcomes on patients treated with endoscopic therapy for barrett’s related neoplasia from the uk registry
Authors: R Haidry, G Lipman, A Gupta, J Dunn, H Smart, P Bhandari, R Willert, G Fullarton, M di Pietro, C Gordon, I Penman, P Boger, N Ravi, Y Ang, M Novelli, LB Lovat
Journal: Gut (2015)

<h3>Introduction</h3> Endoscopic therapy with combined Endoscopic mucosal resection (EMR) followed by Radiofrequency ablation (RFA) is now the recommended first line treatment for patients with Barrett’s (BE) related neoplasia confined to the oesophageal mucosa. <h3>Method</h3> We examine prospective data from the United Kingdom registry of patients undergoing RFA/EMR for BE neoplasia since 2008. Before RFA, visible lesions and nodularity were entirely removed by EMR. Thereafter patients underwent RFA 3 monthly until all visible BE was ablated or cancer developed (endpoints). Biopsies were taken at 12 months or when endpoints reached. Follow up endoscopies were performed periodically in all patients to check for recurrences thereafter. All patients who had completed at least 12 months of follow up after successful treatment were included in the analysis to examine durability of disease reversal long term. <h3>Results</h3> 282 patients (81% male, mean age 70 years) have completed the 12 month treatment protocol with a minimum of 12 months follow up thereafter. At median follow up of 37 months (IQR 29–49), 93% of patients with successful disease reversal were still free of neoplasia and 88% free of intestinal metaplasia recurrence. Cancer progression at this same time was seen in 1.4% of patients. Kaplan Meier (KM) statistics demonstrated a predicted 3 year neoplasia free survival in 88% of patients. At 5 and 6 years this was 86%. Similarly KM analysis showed that at 3 years 81% of patients would be free form BE and at 5 and 6 years this figure was 73%. <h3>Conclusion</h3> We report long term outcomes of a large cohort of patients with BE neoplasia who have had successful endoscopic therapy with RFA/EMR. This approach appears to have a lasting disease free benefit in the majority of patients. Recurrences do occur in a minority of patients and highlights the need for follow up in those fit for endoscopy. <i><b>All collaborators of the UK RFA registry are acknowledged for their contributions to data collection for this work</b>.</i> <h3>Disclosure of interest</h3> None Declared.
P01.077 Optimizing array layouts for glioblastoma therapy with tumor treating fields (TTFields) - Use of oblique array layouts surpass default left-right/anterior-posterior positions in a computer simulation model
Authors: A R Korshoej, N Mikic, J H Sørensen, G B von Oettingen
Journal: Neuro-Oncology (2018)

Tumor treating fields (TTFields, Optune®) is an effective treatment for glioblastoma. The antimitotic effects of TTFields are induced by low-intensity, intermediate frequency (200 kHz) alternating electric fields, delivered through two pairs of transducer arrays placed on the patient’s scalp. The present study aimed to identify optimal array positions that induced the highest electric field in the tumor by analyzing systematic variations in array layouts. TTFields distribution was computed using finite element methods with a realistic computational head model. A standard anterior-posterior (AP) layout was rotated in 15-degree intervals in the same plane around a central cranio-caudal axis of the head to investigate thirteen array positions. During subdivision, tumors were placed at nineteen different frontoparietal positions in the array rotation plane. TTFields distribution was affected by different array layouts. Two array layouts were identified to be suitable for most tumors. These identified positions led to TTFields intensities that were approximately 30–40% higher in the tumors than in standard AP and left/right (LR) layouts. The two optimal layouts were oriented at 90-degree intervals to each other. Subsequent analysis of combining two array pairs revealed a single optimum layout. For each tumor position, only one optimum layout combination was identified, which was usually oriented in 15–45 degree angles relative to the sagittal plane. In each case, an oblique layout that was orientated at 45 degrees to the sagittal plane was effective for most tumor localizations and superior to the default AP/LR layout combination. Determining factors for layout optimization were high field intensities at transducers located on the edges of the arrays, with high fields close to the peripheral transducers. The present study provides guiding principles for optimal TTFields layout design and planning. Individual patient-specific models should be used to determine TTFields distributions more accurately.
Interruption of Cell-Cell Communication in Chinese Hamster V79 Cells by Various Alkyl Glycol Ethers: Implications for Teratogenicity
Authors: Rita Loch-Caruso, James E. Trosko, Isabel A. Corcos
Journal: Environmental Health Perspectives (1984)

Intercellular communication most likely plays a significant coordinating role in morphogenesis. Blockage of a specific type of intercellular communication, that mediated by gap junctions, has been proposed as a mechanism of action of some teratogens. Several glycol ethers have recently been shown to be teratogenic in laboratory animals. Because these compounds are negative in genotoxic assays, it is suggested that they may act by nongenetic, perhaps membrane-mediated mechanisms. In the present study several structurally related alkyl glycol ethers were examined for their ability to block junction-mediated intercellular communication. Interruption of intercellular communication was measured in vitro by an assay that depends on the transfer of metabolites via gap junctions, i.e., metabolic cooperation. All compounds tested--ethylene glycol (EG), ethylene glycol monomethyl ether (EGME), ethylene glycol monoethyl ether (EGEE), ethylene glycol monopropyl ether (EGPE), and ethylene glycol monobutyl ether (EGBE)--were able to block metabolic cooperation in vitro. The potencies of the compounds were inversely related to the length of the aliphatic chain, the dose required for maximum blockage increasing as the aliphatic chain shortened. Some differences in the maximum amount of blockage were detected, but these were not consistent and hence were not considered significant. Cytotoxicity, as measured by cell survival, was also related to the structure of the compound, generally increasing with increased length of the aliphatic chain. There were structurally related differences in the concentration ranges over which the compounds were effective.(ABSTRACT TRUNCATED AT 250 WORDS)
Can induction chemotherapy improve dysphagia in locally advanced esophageal/GEJ cancer?
Authors: Elizabeth Won, David H. Ilson, Jessica Herrera, Yelena Yuriy Janjigian, Geoffrey Yuyat Ku, Nabil P. Rizk, Inderpal S. Sarkaria, Valerie W. Rusch, Prasad S. Adusumili, Manjit S. Bains
Journal: Journal of Clinical Oncology (2014)

4010 Background: Dysphagia is one of the most common presenting symptoms in esophageal cancer (EC) and can lead to significant nutritional decline, which is associated with increased toxicity and poor outcomes. Invasive feeding tubes (FT) or endoscopic stents are frequently used to improve nutrition in this setting. We evaluated the role of induction chemotherapy prior to concurrent chemoradiation as presurgical treatment in improving dysphagia. Methods: Retrospective analysis of 4 prospective studies conducted at MSKCC with induction chemotherapy followed by concurrent chemoRT and surgery in locally advanced esophageal/GEJ cancer. Regimens included cisplatin/paclitaxel, cisplatin/irinotecan, and cisplatin/irinotecan/bevacizumab. Dysphagia was graded prospectively using a validated dysphagia scale. Response of dysphagia and nutritional status to induction chemotherapy was evaluated. Results: Of 161 patients (pts) undergoing induction chemotherapy, [median age 59(21-76), KPS 90 (70-100), 77% adenocarcinoma], 121 (76%) had dysphagia, with 59(37%) with grade 2 dysphagia or higher (20% Stage II, 80% Stage III). 6(4%) required EGD dilatation/stent and none required FT placement prior to treatment. 22% pts had>10% body weight loss prior to treatment and average weight loss in all pts was 4.3kg. After induction chemotherapy, 103 (65%) had improvement in dysphagia. This was associated with a weight gain in 42% of pts. Only 7(4%) had worsening dysphagia after induction chemotherapy: 4/7 required FT (2% of all pts), 2/7 EGD intervention (1% of all pts). 6/7 of these pts with worsening dysphagia had poor short term outcomes: 2/7 progressive disease, 3/7 unresectable, 1/7 post-operative death. Conclusions: Induction chemotherapy prior to concurrent chemoradiation for locally advanced esophageal cancer can effectively improve swallowing and nutritional status, while mitigating need for feeding tubes or stents in patients with significant dysphagia. Post-induction dysphagia may be prognostic and merits further investigation. Research supported by Foundation 14.
Medical manpower.
Authors: S Brearley
Journal: BMJ (1991)

cannot see that happening because they are an essential part of our educational fabric.The special health authorities are the nearest we have to the United States' National Institutes of Health.Their future cannot be judged in short term market terms.RS: But might not the Hammersmith follow the model of some of the top hospitals in the United States and charge a premium price for treating difficult cases from all over the country?js: It would mean having a very different structure, including having highly developed marketing and lots of private facilities.I can't see that being reasonable at the moment.In some respects the American health care systems have more problems than our own.&..
LONDON
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HYGIENE.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Euthanasia
Authors: M. Bliss, M. Brayshay, C. Brewer, M R A Chance, D. Clark, A C Dalzell, M R Davies, W H B Ellis, D Gairdner, T Glanvill, M. Hare, S L H. Smith, P L Lewis, M L Millard, K Norcross, S N Ray, A Roberts, S C Truelove, S T Williams
Journal: BMJ (1987)
Never tell a patient 'never' about the use of radiographic contrast agents
Authors: G. D. Dixon
Journal: JAMA (1982)

It has long been an irritation to me that, after a patient experiences contrast media "reactions," physicians or other paramedical personnel will advise him never again to allow radiographic contrast agents—dyes, if you will— to be injected into him. As a diagnostic radiologist, I have recently consulted with three patients who were told this. All of these patients needed contrast studies, and all were unduly concerned about the use of such agents because of previous admonitions by medical personnel. For example: <h3>Case 1.—</h3> A 58-year-old woman was to have a computed tomographic (CT) study of the cerebellopontine angle cistern to rule out an acoustic neuroma. Because of a rather strong allergic history, she had previously been told by a physician never to allow the injection of radiographic contrast agents, despite the fact that she had never had any such injection. After considerable explanation and reassurance on my part and telephone
Editorial Board
Authors: Leonard Wartofsky, Gail Adler, Bradley Anawalt, Janet Hall, Ronald Koenig, Satchidananda Panda, Michael Rickels, Clifford Rosen, Roberto Salvatori, Wiebke Arlt, Richard Eastell, Rossella Elisei, David Handelsman, Alexander Lima, George Mastorakos, Robert Semple, Peter Trainer, Richard O'grady, Timothy Beardsley
Journal: Endocrine Reviews (2017)
Leads from the MMWR. Current Trends. Influenza--United States, 1985-1986 season
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutics.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Encore
Authors: None Gemaennes
Journal: Annals of the Rheumatic Diseases (1990)

EncoreInterleukin 1 and cartilage metabolism Interleukin 1 in bovine cartilage culture leads to prostaglandin E2 release and stimulation of proteoglycan breakdown.This effect is much more potent in inhibiting synthesis of proteoglycan than in breaking it down however, and the effect on proteoglycan occurred earlier than that on prostaglandin release.Non-steroidal anti-inflammatory drugs seemed to have little effect on proteoglycan meta- bolism, but other drugs such as chloroquine did appear to inhibit proteoglycan synthesis.The effects of interleukin 1 on proteoglycan breakdown, its synthesis, and prostaglandin release seem to be independently regulated.
OLD AND NEW KNOWLEDGE OF IMMUNITY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal